News Search Results
Jan 18, 2026, 19:02 ET Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration
warrant was originally issued to Harbour BioMed's subsidiary and other minority shareholders of HBM Alpha Therapeutics ("HBMAT"), an innovative biotechnology company incubated by Harbour BioMed, in connection with a license and collaboration agreement by and between HBMAT and Spruce. The collaboration
More news about: Harbour BioMed
Jan 16, 2026, 18:22 ET 2026 China FIC Innovation and Collaboration Summit Held in San Francisco, Chinese Pharmaceutical Companies Showcase Innovative Achievements
capital, and technology. A complete industrial chain spanning early-stage R&D to clinical production is gradually taking shape, while a cohort of biotechnology companies with global vision is rapidly emerging, providing full-chain support for innovative drug development.From their collective presence
More news about: Beijing Hotgen Biotech Co., Ltd.
Jan 16, 2026, 16:01 ET MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option
Jan. 16, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA) (MetaVia or the Company), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the closing of its previously announced underwritten public offering of
More news about: MetaVia Inc.
Jan 16, 2026, 11:01 ET Doseology Files Annual Information Form (AIF), Strengthening Public Disclosure Record AIF Filing Enhances Transparency and Provides Consolidated Disclosure for Investors
16, 2026 /PRNewswire/ -- Doseology Sciences Inc. (CSE: MOOD) (PINK: DOSEF) (FSE: VU70) ("Doseology" or the "Company") a leader in biotechnology-driven consumer products, today announced that it has filed its Annual Information Form ("AIF"), a key Canadian public-company disclosure
More news about: Doseology Sciences Inc.
Jan 16, 2026, 09:20 ET Vaximm Appoints Sébastien Wieckowski, PhD, as Chief Scientific Officer to Advance Next-Generation Oral Immunotherapy Platform
engagement, combined with high safety and tolerability, is essential."About Vaximm AGVaximm AG is a privately held Swiss-German biotechnology company and a subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH). Vaximm's proprietary oral T-cell immunotherapy platform harnesses live, attenuated
More news about: OSR Holdings
Jan 16, 2026, 08:00 ET Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape
product revenue of approximately $113 million for fiscal year 2025, representing a 700% year-over-year increase for ANKTIVA. The commercial-stage biotechnology company delivered fourth quarter preliminary revenue of approximately $38.3 million, marking a 20% sequential increase and a 431% year-over-year
More news about: Equity Insider
Jan 16, 2026, 05:05 ET Datwyler, LTS Device Technologies, and Stevanato Group Collaborate to Expand Self-Delivery Options for Large-Volume Drugs
GroupFounded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes, and services that address customer
More news about: Datwyler
Jan 16, 2026, 03:30 ET Digital Pathology Market Growing at 9.9% CAGR to 2031 as AI Adoption Accelerates, says a 2026 Mordor Intelligence Report
& Archiving By End User Hospital & Reference Laboratories Pharmaceutical & Biotechnology Companies and CROs Diagnostic Centers Other End Users By Deployment Model On-premise Cloud-based
More news about: Mordor Intelligence Private Limited
Jan 15, 2026, 23:23 ET The AKG and Ca-AKG of Xin Tianhe have passed the US Self-GRAS certification
Jan. 15, 2026 /PRNewswire/ -- On January 7, 2026, the AKG and Ca-AKG of Xin Tianhe Biotechnology successfully completed the Self-GRAS scientific evaluation in accordance with the US FDA GRAS standards and were approved and became the first domestic
More news about: XinTianhe Biotechnology
Jan 15, 2026, 12:00 ET QuantiPath Introduces Expanded À La Carte Multiplex Options
requirements — from high-throughput screening programs to localized investigative testing scenarios.About QuantiPathQuantiPath is a biotechnology company revolutionizing food safety testing through precision genetic diagnostics. Its flagship product, GenoPATHx, is the only rapid test kit that
More news about: QuantiPath
Jan 15, 2026, 10:43 ET Cancer Biomarkers Market Surges to USD 45.7 Billion by 2033, Propelled by 8.6% CAGR - Verified Market Reports®
large patient populations, increasing cancer incidence, and expanding access to diagnostic services. National health reforms and investments in biotechnology infrastructure are enabling local companies to enter the biomarker value chain. Countries such as China, Japan, and South Korea are prioritizing
More news about: Verified Market Reports
Jan 15, 2026, 10:30 ET Drug Discovery Technologies Market worth $51.51 billion by 2031 | MarketsandMarkets™
biological targets. The technology has immense applications in the drug discovery stages of organizations associated with the pharmaceutical and biotechnology industries.Request Sample Pages@
More news about: MarketsandMarkets
Jan 15, 2026, 09:53 ET Turret Capital Launches Sable, a Biotech-Driven Beauty Brand Advancing Body Contouring and Aesthetic Longevity
Capital is a global venture capital firm that specializes in identifying and commercializing transformative healthcare technologies. With a focus on biotechnology and medical innovation, Turret creates and scales companies that address significant unmet needs in human health and wellness.About SOSVSOSV
More news about: Turret Capital Management
Jan 15, 2026, 09:32 ET MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering
Jan. 15, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA) (MetaVia or the Company), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the pricing of its underwritten public offering of shares of common stock
More news about: MetaVia, Inc.
Jan 15, 2026, 09:14 ET Junipr Public Relations Named Agency of Record for The Belfry House; R-to-V Marketing to Lead Digital Strategy
founded in 2019, the company has grown to service B2C and B2B clients across a variety of sectors including the hospitality, food and beverage, biotechnology, CPG, food safety, nonprofit, automotive, and cannabis industries. With a passion to do Smart Work for Nice People™, Junipr's skilled team of strategic
More news about: Junipr Public Relations
Jan 15, 2026, 08:59 ET aXichem Announces Publication of CrossFit Study in Leading Sports Journal - Validates aXivite as a High-Intensity Performance Supplement
aXichem AB (publ), (aXichem), the developer of innovative feed additives and food supplement biotechnology, is pleased to announce the formal publication of its latest clinical trial,
More news about: aXichem AB
Jan 15, 2026, 08:55 ET aXichem Announces Publication of CrossFit Study in Leading Sports Journal - Validates aXivite as a High-Intensity Performance Supplement
aXichem AB (publ), (aXichem), the developer of innovative feed additives and food supplement biotechnology, is pleased to announce the formal publication of its latest clinical trial,
More news about: aXichem AB
Jan 15, 2026, 08:30 ET Continuous Biologics Manufacturing for Modular and Sustainable Operations, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Jan 15, 2026, 08:30 ET Emerging LNP Technology and mRNA Strategies for In Vivo CAR-T Development, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Jan 15, 2026, 08:30 ET Zydus Lifesciences Limited completes the acquisition of Agenus Inc.'s biologics manufacturing facilities, launches Zylidac Bio LLC in the U.S.
significant in light of the BIOSECURE Act, signed into law on December 18, 2025, which restricts U.S. executive agencies from contracting with "Biotechnology Companies of Concern". By establishing a secure, domestic manufacturing footprint in California through Zylidac Bio LLC, Zydus provides a "safe-harbor"
More news about: Zydus Lifesciences Limited
Jan 15, 2026, 07:00 ET Brenig Therapeutics Announces Initiation of First-in-Human Study of BT-409, a Brain-Selective NLRP3 Inhibitor, and Provides Update on BT-267, its LRRK2 Program
BOSTON, Jan. 15, 2026 /PRNewswire/ -- Brenig Therapeutics, Inc. (Brenig), a clinical-stage biotechnology company advancing small-molecule therapies for neurodegenerative diseases, today announced the initiation of a first-in-human (FIH) clinical study
More news about: Brenig Therapeutics Inc
Jan 15, 2026, 06:01 ET First Patients in the UK Receive Doses of Blue Earth Therapeutics' Investigational Radiopharmaceutical Therapy Lutetium (177Lu) rhPSMA-10.1 Injection for Metastatic Castrate Resistant Prostate Cancer
financing round in 2024. With proven management expertise across the spectrum of radiopharmaceutical and oncology drug development, as well as biotechnology start‐up experience, the Company aims to innovate and improve upon current technologies and rapidly advance new targeted therapies for serious diseases.
More news about: Blue Earth Therapeutics Limited
Jan 15, 2026, 04:51 ET Aphranel Convenes Cadaver Dissection Class in Thailand Successfully
https://www.prnewswire.com/news-releases/aphranel-convenes-cadaver-dissection-class-in-thailand-successfully-302662229.htmlSOURCE SHANGHAI MOYOM BIOTECHNOLOGY CO., LTD
More news about: SHANGHAI MOYOM BIOTECHNOLOGY CO., LTD
Jan 14, 2026, 22:34 ET Hyundai Bioscience Confirms Entry into U.S. FDA Phase 2 Trials for Broad-Spectrum Antiviral 'XAFTY' Following 2026 Biotech Showcase Consensus
Hyundai Bioscience:Hyundai Bioscience is a biotechnology company focused on developing novel drug delivery systems (DDS) to repurpose existing drugs for new therapeutic applications. The company is a member
More news about: Hyundai Bioscience
Jan 14, 2026, 17:10 ET Transneural Therapeutics Presents Preclinical Data on Lead Candidate TN-001 at 64th Annual Meeting of ACNP (2026)
Transneural Therapeutics, Inc. (Transneural), a neuroscience-focused biotechnology company aiming to transform the treatment of neuropsychiatric and neurodegenerative diseases with novel pharmacotherapies, today presented new data
More news about: Transneural Therapeutics, Inc.